ABBOTT AXSYM VANCOMYCIN-II ASSAY - MULTICENTER EVALUATION AND INTERFERENCE STUDIES

The authors evaluated the performance characteristics of the Abbott Ax SYM Vancomycin II immunoassay in sera of patients with (n = 93 samples ) and without (n = 327 patients) renal dysfunction. Correlation of van comycin measurements with the Abbott AxSYM Vancomycin, Abbott TDx/TDxF Lx, Syva enzyme-multiplied immunoassay technique (EMIT), DuPont automa ted chemistry analyzer !ACA), and high-performance liquid chromatograp hy methods showed acceptable correlation as indicated by: slope values >0.95, r-values >0.97, y-intercepts <1.7 mu g/ ml, and S-y/x ranging from 9% to 15% of the average vancomycin value. The AxSYM Vancomycin I I assay showed acceptable correlation with AxSYM vancomycin, TDx/TDxFL x, and high-performance liquid chromatography methods in 93 samples fr om patients with renal dysfunction. This monoclonal antibody-based ass ay showed no apparent interference from the presence of human antimous e antibody (HAMA) or the microbiologically inactive vancomycin crystal line degradation product (CDP). The authors conclude that the AxSYM Va ncomycin II assay showed satisfactory agreement with other methods tes ted in this study.